Four biotechs spanning a diverse set of therapy targets are seeking out nearly $400 million in a series of IPOs announced just before the New Year.

Dermatology biotech Menlo Therapeutics is looking to take advantage of the strong IPO window with a $98 million offering.

While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.

If you took charge of a sizable biopharma company in 2017, there was one thing you had to do.

Will this year’s resurgence be sustained in 2018 in the face of a more uncertain environment?

Breakout Labs has backed over 30 companies since it handed out the first batch of grants in 2012.

FLX Bio has boosted its cash supplies with a new $60 million series C round as it starts dosing for its first cancer test.

Tessa Therapeutics raised $80 million in a financing round that will usher its virus-specific T cell immunotherapies through clinical trials.